ERBB2 and gastroesophageal junction adenocarcinoma: In 2024, the FDA approved zolbetuximab‐clzb as a first‐line treatment for adults with locally advanced unresectable or metastatic HER2‐negative gastric or gastroesophageal junction adenocarcinoma positive for CLDN18.2, in combination with chemotherapy [87]; however, a limitation of this study was the lack of immunohistochemistry data on CLDN18.2 to inform treatment decisions.